North America Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Offering, Technology, and End User

List of Tables

The North America coagulation market was valued at US$ 2,712.64 million in 2022 and is expected to reach US$ 4,633.26 million by 2030; it is estimated to grow at a CAGR of 6.9% from 2022 to 2030.

Increasing Prevalence of Blood Disorders Fuel North America Coagulation Market

Hemophilia A is one of the common X-linked recessive disorders and the second most common inherited clotting factor deficiency after von Willebrand disease, according to the National Organization of Rare Disorders. Also, ~1 in 5,000 male infants suffers from hemophilia A in the US. According to the Global Hemophilia Care 2020 study, 393,658 bleeding disorders cases have been recognized and documented worldwide over time, including 241,535 hemophilia cases, 87,729 von Willebrand disease cases, and 64,394 other bleeding disorder cases. According to the National Library of Medicine (NLM), ~30,000-33,000 men were affected by hemophilia in the US in 2020.

As per the reports from the American Cancer Society (CLL), the US recorded ~21,250 new cases of chronic lymphocytic leukemia in 2021. A February 2020 update from the Centers for Disease Control and Prevention (CDC) states that the number of people in the US affected by deep vein thrombosis could reach 900,000 (1 to 2 per 1,000). The same source estimates that in the US 60,000-100,000 Americans die yearly from venous thromboembolism.

According to the US Department of Health & Human Services, ~100,000 Americans were diagnosed with sickle cell disease (SCD) in 2020, which is one of the most commonly inherited blood disorders. In addition, the number of people suffering from SCD is expected to grow by ~30% by 2050. The National Organization for Rare Disorders stated that immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affected ~66 adults per 1 million in the US each year in 2022. Therefore, the rising prevalence of blood disorders drives the coagulation market growth.

North America Coagulation Market Overview

The North America coagulation market is segmented into the US, Canada, and Mexico. North America accounts for a significant market share owing to the growing incidences of blood disorders, increasing occurrence of cardiovascular diseases such as atrial fibrillation (AFib), and the presence of major market players engaged in new and existing product developments. The US holds the largest share of the coagulation market in North America. The burgeoning cases of blood disorders, growing prevalence of cardiovascular diseases, and government support for preventing blood disorders are anticipated to boost the North America coagulation market growth during 2022-2030.

North America Coagulation Market Revenue and Forecast to 2030 (US$ Million)

North America Coagulation Market Segmentation

The North America coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the North America coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest North America coagulation market share in 2022.

Based on type, the North America coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger North America coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the North America coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger North America coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the North America coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest North America coagulation market share in 2022.

By end user, the North America coagulation market is segmented into clinical laboratories, hospitals, and others. The clinical laboratories segment held the largest North America coagulation market share in 2022.

Based on country, the North America coagulation market is categorized into the US, Canada, and Mexico. The US dominated the North America coagulation market in 2022.

Diagnostica Stago Inc, F Hoffmann-La Roche Ltd, Genrui Biotech Co, Ltd, Helena Laboratories Corporation, Horiba Ltd, ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti., Siemens Healthineers AG, Sysmex Corp, and Transasia Bio-Medicals Ltd are some of the leading companies operating in the North America coagulation market.

Product Code: BMIRE00029854

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Coagulation Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Increasing Prevalence of Blood Disorders
- 4.1.2 Rising Prevalence of Cardiovascular Diseases
4.2 Market Restraints
- 4.2.1 High Costs Associated with Coagulation Analyzers
4.3 Market Opportunities
- 4.3.1 Growing Organic and Inorganic Strategies by Key Market Players
4.4 Future Trends
- 4.4.1 Development of Point-of-Care (POC) Coagulation Analyzers
4.5 Impact Analysis

5. Coagulation Market - North America Market Analysis

5.1 North America Coagulation Market Revenue (US$ million), 2022 - 2030

6. North America Coagulation Market - Revenue and Forecast to 2030 - by Disease Indication

6.1 Overview
6.2 North America Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
6.3 Vitamin K Deficiency
- 6.3.1 Overview
- 6.3.2 Vitamin K Deficiency: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Liver Disease
- 6.4.1 Overview
- 6.4.2 Liver Disease: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Disseminated Intravascular Coagulation and Pulmonary Embolism
- 6.5.1 Overview
- 6.5.2 Disseminated Intravascular Coagulation and Pulmonary Embolism: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Development of Circulating Anticoagulant
- 6.6.1 Overview
- 6.6.2 Development of Circulating Anticoagulant: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
6.7 Hemophilia
- 6.7.1 Overview
- 6.7.2 Hemophilia: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
6.8 Von Willebrand's Disease
- 6.8.1 Overview
- 6.8.2 Von Willebrand's Disease: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
6.9 Others
- 6.9.1 Overview
- 6.9.2 Others: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Coagulation Market - Revenue and Forecast to 2030 - by Type

7.1 Overview
7.2 North America Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Clinical Laboratory Analyzers
- 7.3.1 Overview
- 7.3.2 Clinical Laboratory Analyzers: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.1 North America Coagulation Market, by Clinical Laboratory Analyzers
7.4 Point-of-Care Testing Analyzers
- 7.4.1 Overview
- 7.4.2 Point-of-Care Testing Analyzers: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Coagulation Market - Revenue and Forecast to 2030 - by Offering

8.1 Overview
8.2 North America Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
8.3 Diagnosis
- 8.3.1 Overview
- 8.3.2 Diagnosis: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 North America Coagulation Market, by Diagnosis
8.4 Treatment
- 8.4.1 Overview
- 8.4.2 Treatment: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 North America Coagulation Market, by Treatment

9. North America Coagulation Market - Revenue and Forecast to 2030 - by Technology

9.1 Overview
9.2 North America Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
9.3 Optical Technology
- 9.3.1 Overview
- 9.3.2 Optical Technology: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Mechanical Technology
- 9.4.1 Overview
- 9.4.2 Mechanical Technology: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Electrochemical Technology
- 9.5.1 Overview
- 9.5.2 Electrochemical Technology: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Coagulation Market - Revenue and Forecast to 2030 - by End User

10.1 Overview
10.2 North America Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
10.3 Clinical Laboratories
- 10.3.1 Overview
- 10.3.2 Clinical Laboratories: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Hospitals
- 10.4.1 Overview
- 10.4.2 Hospitals: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
10.5 Others
- 10.5.1 Overview
- 10.5.2 Others: North America Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Coagulation Market - Country Analysis

11.1 North America Coagulation Market, Revenue and Forecast to 2030

12. Coagulation Market-Industry Landscape

12.1 Overview
12.2 Growth Strategies in the Coagulation Market
12.3 Inorganic Growth Strategies
- 12.3.1 Overview
12.4 Organic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Siemens Healthineers AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Diagnostica Stago, Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sysmex Corp
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Helena Laboratories Corporation
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 F. Hoffmann-La Roche Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Genrui Biotech Co., Ltd.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Transasia Bio-Medicals Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Horiba Ltd.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms